Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06932172

Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care

Background: Artificial intelligence has in numerous studies shown high accuracy in detecting skin cancer when trained on various databases of dermatoscopic images. However, there are very few prospective studies conducted in real clinical settings directed at patients seeking healthcare for assessment of skin lesions, and nosuch studies at all in primary care, where the majority of patients are managed.

Project aim: To study the accuracy, reliability, and clinical utility of an AI-based decision support system (Dermalyser), developed for primary care, in distinguishing skin cancer from benign lesions.

Method: Cluster-randomized controlled trial at approx. 30 primary care centers in Sweden, Germany, Scotland, the Netherlands and Australia. At study start, the participating primary care centres in each country are equally randomised to either be enabled to use the Dermalyser (intervention phase) or to assess patients according to the standard clinical procedure (control phase). When half of the intended sample size (i.e. 1500 of 3000 participants) have been included, the primary care centres switch phase from intervention to control, or vice versa. During the intervention phase, the physicians may use (if found indicated) Dermalyser as a part of their clinical evaluation, whereas during the control phase the physicians follow their ordinary diagnostic routine without support from Dermalyser. This will direct the participants to either an intervention or a control cohort. Both groups will be followed for up to 5 years, with regard to the tumour diagnoses, proportions of skin cancer/benign lesions, and morbidity and mortality in skin cancer. Possible between-group differences will be investigated statistically.

Potential benefits: If the Dermalyser prooves to be safe and diagnotically reliability, it could enhance the chance of detecting skin cancer in early stage in primary care, and to reduce the proportion of benign skin lesion unnecessarily excised or referred to dermatologist.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Finspång Primary Healthcare Centre, Finspång, Docent, Sweden

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients attending a primary care facility in order to have one or more skin lesions checked for skin cancer, or patients presenting with one or more skin lesions raising suspicion of skin cancer when noticed by the primary care physician.
  • Willingness and ability to provide informed consent.

Exclusion criteria

  • Individuals with skin type V and VI according to the Fitzpatrick's scale (darker brown or black coloured skin)

Treatment and study plan

Artificial inteligence based decision support to detect skin cancer

Device

When assessing skin lesions in patients seeking primary care, the primary care physician may use the device to be evaluated in the study (Dermalyser) as a complementary diagnostic doecision support to differentiate skin cancers from benign skin lesions. However, the decision on clinical management of the lesion remains with the physician.

Primary outcomes

  1. Proportion of skin cancers

    Time frame: From enrollment until all included lesions have been diagnosed following standard clinical investigation procedure, which we consider in the normal case will not exceed 6 months from inclusion.

    Proportion of skin cancers (melanoma, SCC or BCC) excised or referred to dermatologists, as described in percentage of total number of skin lesions included.

Study contacts

Contact information is provided by the study sponsor or research team.

Magnus Falk, Professor

CONTACT

[email protected]

+46708106176

Panos Papachristou, MD, PhD

CONTACT

[email protected]

+46702298892

Sponsors and collaborators

Lead sponsor

Linkoeping University

Other Gov

Collaborators

  • Göteborg University
  • Karolinska Institutet
  • Region Östergötland

Registry information

Official study title

Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care - a Multicentre Randomized Controlled Trial.

Acronym: AI-DSSC

Important dates

Study start
2025
Primary completion
2027
Study completion
2031
First posted
Apr 17, 2025
Registry last updated
Jan 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.